RCS - Kanabo Group PLC - UK Moves to License e-cigarettes and vaporizers

KanaboAnnouncement

06/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211206:nRSF5960Ua&default-theme=true

RNS Number : 5960U  Kanabo Group PLC  06 December 2021

Kanabo Group Plc

("Kanabo" or the "Company")

UK Moves to License e-cigarettes and vaporizers

Kanabo Group Plc (LSE:KNB), a medical cannabis and R&D Company that
focuses on the distribution of cannabis-derived products for medical patients
and wellness CBD consumers, welcomes news that the UK could be the first
country in the World to prescribe medicinally licensed  e-cigarettes and
Vaporizers

 

New UK Guidelines

The U.K government agency, Medicines and Healthcare Products Regulatory Agency
("MHRA") has announced that the UK's National Health Service ("NHS") could
soon prescribe e-cigarettes to help patients stop smoking tobacco products.

 

To achieve a licence, products would need to meet the standards of quality,
safety, and efficacy expected of medicinal products. If successful, this would
potentially allow safe and effective products to be made available for
prescription, for tobacco smokers who wish to quit or reduce smoking.

 

The updated guidance provides further details on the steps required to license
an e-cigarette as a medicinal product and has invited e-cigarette
manufacturers to submit products to undergo the same approval process as
prescribed medicines. This could make the UK the first country to prescribe
medicinally licensed e-cigarettes.

 

If a product receives MHRA approval, clinicians could then decide on a
case-by-case basis whether it would be appropriate to prescribe an e-cigarette
to NHS patients to help them quit smoking.

 

Dr June Raine, Chief Executive of the MHRA, said: "The evidence is clear that
e-cigarettes are less harmful to health than smoking tobacco and that
nicotine-containing e-cigarettes can help people quit smoking for good. The
updated guidance on licensing requirements we have published today is a strong
first step towards availability of safe and effective licensed e-cigarette
products.

 

The MHRA will continue to support companies in the development of safe and
effective e-cigarette products, to encourage the licensing of e-cigarette
products as medicines in order to support patient-centred care and access."

 

The UK's Health and Social Care Secretary Sajid Javid said: "This country
continues to be a global leader on healthcare, whether it's our COVID-19
vaccine roll-out saving lives or our innovative public health measures
reducing people's risk of serious illness.

 

Opening the door to a licensed e-cigarette prescribed on the NHS has the
potential to tackle the stark disparities in smoking rates across the country,
helping people stop smoking wherever they live and whatever their background."

 

Avihu Tamir, CEO of Kanabo Group said, "Any research that helps patients has
to be welcomed. Kanabo started its commercial life by addressing the issue of
developing a device to deliver a reliable and repeatable metered dose of
medicinal cannabis to help patients combat their ailments.  The Company's
proprietary VapePod is now a class-leading medical device available in the UK.
As the UK's regulatory framework outlines a higher entry barrier for the
industry, the global vaping industry will witness a more standardised and
concentrated market where industry leaders, such as Kanabo, will further
strengthen their leading positions. Meanwhile, the whole industry, the supply
chain and patients will benefit from such a well-regulated and standardised
market in turn."

 

 

For further information, please visit http://www.kanabogroup.com/ or contact
the following:

 Kanabo Group Plc
 Avihu Tamir, CEO                                       Via Vox Markets
 Peterhouse Capital Ltd
 Eran Zucker (Financial Adviser)                        Tel: +44 (0)20 7469 0930
 Lucy Williams / Charles Goodfellow (Corporate Broker)  Tel: +44 (0)20 7469 0930
 Vox Markets (Investor Relations)
 Kat Perez                                              KanaboGroup@voxmarkets.co.uk

 

About Kanabo Group Plc

Kanabo Group Plc is an R&D company currently selling a range of wellness
CBD Products in the Primary Markets and Medical Cannabis Products. The
company's core strategy is to increase revenues from the sale of its Retail
CBD Products in the wellness sector and to grow the Kanabo brand through its
marketing initiatives.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFSSFAIEFSELE